NCT04005690 - Targeted Pathway Inhibition in Patients With Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

June 1, 2026

Study Completion Date

February 1, 2028

Conditions

Locally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Ductal AdenocarcinomaBorderline Resectable Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal Adenocarcinoma

Interventions

DRUG

Cobimetinib

Given PO

DRUG

Olaparib

Given PO

DRUG

Onvansertib

Given PO

DRUG

Azenosertib

Given PO

DRUG

Saruparib

Given PO

BIOLOGICAL

Tremelimumab

Given IV

Trial Locations (1)

97239

RECRUITING

OHSU Knight Cancer Institute, Portland